Ernexa reports ERNA-101 plus PD-1 blockade clears tumors in ovarian cancer models

Eterna Therapeutics

Eterna Therapeutics

ERNA

0.00
  • Ernexa Therapeutics on May 6, 2026 reported new preclinical results for lead cell therapy candidate ERNA-101 used with PD-1 blockade in ovarian cancer models; results were presented with this announcement.
  • Combination treatment produced complete tumor elimination in tested models, outperforming either approach alone.
  • Studies showed durable long-term survival in treated animals, supporting a potential curative profile in these models.
  • Data point to tumor microenvironment remodeling that could make checkpoint inhibitors more effective in immunologically “cold” tumors.
  • Program positioned to support a first-in-human study in advanced ovarian cancer, with additional combination work underway to broaden potential solid-tumor use.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605060833PRIMZONEFULLFEED9714291) on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.